Crystallization process for preparing high-crystallinity myo-inositol with large particle size and application

A technology with high crystallinity and inositol, which is applied in the crystallization process and application field of inositol, can solve the problems of unavoidable agglomeration and crystal fragmentation, product residue cannot be removed, and the content of inositol is reduced, so as to avoid agglomeration and agglomeration Agglomerates and crystal fragmentation, avoiding agglomeration and crystal fragmentation, and improving high temperature and high humidity stability

Active Publication Date: 2016-06-15
ZHUCHENG HAOTIAN PHARMA
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The use of glycerin or glycerides may lead to the residues in the product that cannot be removed, resulting in a decrease in the content of inositol
At the same time, the above two methods for preparing inositol crystals do not avoid the generation of dihydrate crystal form H, and still cannot avoid the phenomenon of agglomeration and crystal fragmentation in the drying process.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystallization process for preparing high-crystallinity myo-inositol with large particle size and application
  • Crystallization process for preparing high-crystallinity myo-inositol with large particle size and application
  • Crystallization process for preparing high-crystallinity myo-inositol with large particle size and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Suspend 200g of fine inositol in 200g of ultrapure water, raise the temperature to 95°C, filter, add 10g of type I inositol seed crystals to the clear solution, keep the temperature for 1h, and then program the temperature drop at a rate of 3°C / h. When the temperature dropped to room temperature, it was filtered, and the wet product of inositol was dried in a blast drying oven at 50° C. to obtain 190 g of inositol crystals with a yield of 95%.

Embodiment 2

[0036] Suspend 200g of fine inositol in 300g of ultra-pure water, raise the temperature to 85°C, filter, add 10g of type I inositol seed crystals to the clear solution, keep the temperature for 1h, and then program the temperature down at a rate of 3°C / h. When the temperature dropped to room temperature, it was filtered, and the wet product of inositol was dried in a blast oven at 50° C. to obtain 176 g of inositol crystals with a yield of 88%.

Embodiment 3

[0038] Suspend 200g of fine inositol in 500g of ultra-pure water, raise the temperature to 65°C, filter, add 10g of type I inositol seed crystals to the clear solution, keep the temperature for 1h, and then program the temperature drop at a rate of 3°C / h. When the temperature dropped to room temperature, it was filtered, and the wet product of inositol was dried in a blast oven at 50° C. to obtain 164 g of inositol crystals with a yield of 82%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention belongs to the technical field of medicament crystallization processes, and discloses a crystallization process for preparing high-crystallinity myo-inositol with a large particle size. A product prepared by the crystallization process is columnar crystalline myo-inositol, a particle size thereof can be more than 100 microns, the product is high in crystallinity and uniform in particle size distribution, and the shortcomings of low content, high moisture absorption and caking rate, long suction filtration and drying time, poor flowability and the like of powdery myo-inositol prepared by the prior art are overcome. The crystallization process has the characteristics of process simplicity, low equipment requirements and the like, production of a dihydrate crystal form H in a process is avoided, caking and crystal breaking in a drying process are avoided, suction filtration and drying time is shortened, and process cost is reduced.

Description

technical field [0001] The invention belongs to the technical field of medicine crystallization technology, and in particular relates to a crystallization technology and application for preparing inositol with high crystallinity and large particle size. Background technique [0002] The chemical name of myo-inositol is: cis-1, 2, 3, 5-trans-4, 6-cyclohexyl alcohol, and its chemical structure is as follows: [0003] [0004] Inositol was first isolated from muscle tissue by Scherer in 1850, hence the name inositol. Inositol mainly exists in nature in two forms: phosphoinositol and phytate. The former is mainly distributed in animal and microbial cells as a component of cells; while the latter mainly exists in natural plants. [0005] Today, myo-inositol has been used in food industry, pharmaceutical industry, feed industry and cosmetics industry and other fields, and the market prospect is very broad. According to statistics, the main consumer markets of inositol are the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07C29/78C07C35/16A61K31/047A61K8/34A23L33/10
CPCA23V2002/00A61K8/345A61K31/047C07B2200/13C07C29/78C07C35/16A23V2200/30A23V2200/324A23V2250/08
Inventor 朱理平梅雪锋黄颖王建荣
Owner ZHUCHENG HAOTIAN PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap